U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07311200) titled 'A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)' on Dec. 16.
Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.
Study Start Date: Jan. 15, 2026
Study Type: INTERVENTIONAL
Condition:
Active Systemic Lupus Erythematosus
Intervention:
DRUG: D-2570
Participants will be assigned to one of the following groups: Group A, Group B, Group C, or the placebo control group.
DRUG: D-2570 Placebo
D-2570 Placebo
Recruitment Status: NOT_YET...